Sensei Biotherapeutics, Inc. announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 ? June 4, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | +1.66% | +46.03% | +165.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+165.90% | 46.15M | |
+2.93% | 108B | |
-2.97% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting